NCT06423950 Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
| NCT ID | NCT06423950 |
| Status | Recruiting |
| Phase | — |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Condition | Pediatric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 35 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35 participants in total. It began in 2024-05-01 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the ability of a multidisciplinary and multisite group, the Pediatric Evolutionary Tumor Board (pedsETB), to develop additional therapeutic strategies in patients without curative options or with suboptimal outcomes.
Eligibility Criteria
Inclusion Criteria: * Participant must be considered likely incurable given the standard of care. This is inclusive of patients newly diagnosed, relapsed or in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but unlikely curative options for care. The site investigator will make this determination based on their experience. * Participant must have an age-appropriate performance status: Karnofsky 50 or more for patients 16 years of age or older OR Lansky score of 50 or more for patients less than16 years of age. * Participant and/or parents or legal guardian and primary oncologist must be willing to consider the therapeutic strategies recommended by the pedsETB. * Participant must be willing to be followed over time and allow collection of clinical data including scans, available blood and lab samples, and optional pedsETB serial blood sampling. * All Participants and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document. Exclusion Criteria: * Participants without known therapies to reliably induce a response are excluded from pedsETB and should seek clinical trials.
Contact & Investigator
Jonathan Metts, MD
PRINCIPAL INVESTIGATOR
Moffitt Cancer Center
Frequently Asked Questions
Who can join the NCT06423950 clinical trial?
This trial is open to participants of all sexes, studying Pediatric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06423950 currently recruiting?
Yes, NCT06423950 is actively recruiting participants. Contact the research team at Jessica.Crimella@moffitt.org for enrollment information.
Where is the NCT06423950 trial being conducted?
This trial is being conducted at Hartford, United States, Tampa, United States, Buffalo, United States.
Who is sponsoring the NCT06423950 clinical trial?
NCT06423950 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Jonathan Metts, MD at Moffitt Cancer Center. The trial plans to enroll 35 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.